Key Performance
More- Earnings Score: 51
- Momentum Score: 29
- True Yield: 78
- Financial Health Score: 40
%20scale(1,1)}%2025%25%20{transform:%20translate(24.943161px,19.954806px)%20scale(0.85,0.85)}%2050%25%20{transform:%20translate(24.943161px,19.954806px)%20scale(0.7,0.7)}%2075%25%20{transform:%20translate(24.943161px,19.954806px)%20scale(0.85,0.85)}%20100%25%20{transform:%20translate(24.943161px,19.954806px)%20scale(1,1)}}%20%23ewMkZ6d8Hun3_ts%20{animation:%20ewMkZ6d8Hun3_ts__ts%204000ms%20linear%20infinite%20normal%20forwards}@keyframes%20ewMkZ6d8Hun3_ts__ts%20{%200%25%20{transform:%20translate(24.9787px,20.012362px)%20scale(1,1)}%2025%25%20{transform:%20translate(24.9787px,20.012362px)%20scale(0.85,0.85)}%2050%25%20{transform:%20translate(24.9787px,20.012362px)%20scale(0.7,0.7)}%2075%25%20{transform:%20translate(24.9787px,20.012362px)%20scale(0.85,0.85)}%20100%25%20{transform:%20translate(24.9787px,20.012362px)%20scale(1,1)}}%20]]%3e%3c/style%3e%3cdefs%3e%3clinearGradient%20id='ewMkZ6d8Hun2-fill'%20x1='12.5'%20y1='23.5001'%20x2='-0.868518'%20y2='16.4047'%20spreadMethod='pad'%20gradientUnits='userSpaceOnUse'%20gradientTransform='translate(0%200)'%3e%3cstop%20id='ewMkZ6d8Hun2-fill-0'%20offset='0%25'%20stop-color='%23FF2F00'/%3e%3cstop%20id='ewMkZ6d8Hun2-fill-1'%20offset='100%25'%20stop-color='%23FF9100'/%3e%3c/linearGradient%3e%3clinearGradient%20id='ewMkZ6d8Hun3-fill'%20x1='31.5059'%20y1='27.1026'%20x2='10.2884'%20y2='14.9373'%20spreadMethod='pad'%20gradientUnits='userSpaceOnUse'%20gradientTransform='translate(0%200)'%3e%3cstop%20id='ewMkZ6d8Hun3-fill-0'%20offset='4.7%25'%20stop-color='%23FF2F00'/%3e%3cstop%20id='ewMkZ6d8Hun3-fill-1'%20offset='100%25'%20stop-color='%23FF9100'/%3e%3c/linearGradient%3e%3c/defs%3e%3cg%20id='ewMkZ6d8Hun2_ts'%20transform='translate(24.943161,19.954806)%20scale(1,1)'%3e%3cpath%20d='M14.8466,29.2814c0,0-14.408088-4.6983-12.05895-19.79995c0,0,1.50345,4.85085,4.13448,5.30845s-2.03592,4.6373,7.92447,14.4915Z'%20transform='translate(-24.943161,-19.954806)'%20fill='url(%23ewMkZ6d8Hun2-fill)'/%3e%3c/g%3e%3cg%20id='ewMkZ6d8Hun3_ts'%20transform='translate(24.9787,20.012362)%20scale(1,1)'%3e%3cpath%20d='M37.4922,21.9282l4.0719.244v-12.81353C31.0713,3.28748,17.7595,7.6502,17.7595,7.6502c.3445-4.51526-3.5707-5.52204-3.5707-5.52204c2.5371,1.52542.3132,6.22373.3132,6.22373C13.0299,0.084092,0,1.02986,0,1.02986C8.92672,4.35528,6.70287,7.98579,6.8908,16.6197c.18794,8.6034,8.3943,12.9966,8.3943,12.9966l-6.60895-.2441v13.2407c0,0,5.48135,2.3797,13.68765,3.1729v-22.3017h-4.4477c-1.0023,0-1.942-.8237-1.942-1.8v-5.7356c0-.9763.9397-1.8,1.942-1.8h4.4477v-1.3424h5.0115v1.3424h5.0115c1.0023,0,1.848.7932,1.848,1.8v5.7356c0,.9763-.8144,1.8-1.848,1.8h-5.0115v22.5153h.2819c11.1192-.0611,15.9428-7.3221,16.256-13.3017.4698-7.7492-6.421-10.7695-6.421-10.7695Z'%20transform='translate(-24.9787,-20.012361)'%20fill='url(%23ewMkZ6d8Hun3-fill)'/%3e%3c/g%3e%3c/svg%3e)
Latest Research & News
The global laboratory equipment services market is projected to grow from USD 28.94 billion in 2025 to USD 62.83 billion by 2035, at a CAGR of 8%. Growth is driven by increased R&D investments in life sciences, stricter regulatory compliance requirements, expansion of biopharma facilities, and adoption of IoT-enhanced predictive maintenance technologies. Repair and maintenance services represent the largest market segment, with North America dominating and Asia Pacific showing the fastest growth.
06/24/2026, 3:30 PM • GlobeNewswire
Danaher's stock has fallen 22% this year following its $9.9 billion acquisition of Masimo, which expands the company into clinical patient monitoring. Despite integration risks and a patent dispute with Apple, Danaher reported strong Q1 results with 3% revenue growth and raised 2026 EPS guidance. The company is seeing 30% year-over-year growth in equipment orders, benefiting from a resurgence in life sciences M&A activity. Trading at 20x forward earnings—below its historical average—the stock may represent a buying opportunity if management successfully integrates Masimo.
06/24/2026, 1:35 PM • The Motley Fool
Enteric Disease Testing Market Worth USD 5.86 Billion by 2035 | SNS Insider
The global Enteric Disease Testing Market is valued at USD 4.08 billion in 2025 and is projected to reach USD 5.86 billion by 2035, growing at a CAGR of 3.70%. Growth is driven by increasing foodborne and waterborne disease prevalence, rising demand for rapid pathogen detection, and expanding adoption of multiplex molecular diagnostics. North America and Europe are leading markets, with Asia-Pacific emerging as the fastest-growing region.
06/23/2026, 4:35 AM • GlobeNewswire
The global automated liquid handling systems market is valued at USD 2.7 billion in 2025 and is projected to reach USD 6.9 billion by 2035, growing at a CAGR of 9.8%. Growth is driven by increasing pharmaceutical R&D, clinical trials, technological advancements, and demand for automation in diagnostics and molecular testing. Key players include Eppendorf SE, PerkinElmer Inc., Thermo Fisher Scientific Inc., and QIAGEN NV.
06/18/2026, 10:30 PM • GlobeNewswire
The global chemiluminescence immunoassay (CLIA) market is projected to grow from USD 11.58 billion in 2026 to USD 16.39 billion by 2031, with a CAGR of 7.2%. Growth is driven by rising demand for high-sensitivity diagnostic testing, automated laboratory systems, increasing prevalence of chronic and infectious diseases, and technological advancements including AI-enabled automation. Asia Pacific is emerging as a high-growth region, while hospitals lead market adoption.
06/05/2026, 10:30 AM • GlobeNewswire
The global tissue diagnostics market is projected to grow from USD 6.45 billion in 2025 to USD 9.33 billion by 2031, with a CAGR of 6.35%. Growth is driven by increasing cancer prevalence, rising adoption of precision medicine, advancements in digital pathology and AI-assisted diagnostics, and expanding biomarker-based testing. North America leads the market while Asia-Pacific emerges as a high-growth region.
05/21/2026, 3:37 AM • GlobeNewswire
Global Cervical Cancer Diagnostics Market to Exhibit Growth at a CAGR of ~5% by 2034 | DelveInsight
The cervical cancer diagnostics market is projected to grow from USD 4.4 billion in 2025 to USD 7.1 billion by 2034 at a CAGR of ~5%. Growth is driven by rising cervical cancer prevalence, increasing adoption of advanced diagnostic technologies like HPV testing and AI-powered screening tools, government screening initiatives, and expanding healthcare infrastructure particularly in emerging economies. North America leads the market with 44% share in 2025.
05/14/2026, 1:00 PM • GlobeNewswire
The global pregnancy detection kits market is projected to grow from USD 1.91 billion in 2025 to USD 2.69 billion by 2031, with a CAGR of 5.87%. Growth is driven by technological advancements enabling earlier detection, rising infertility rates, and increasing adoption of digital integration and e-commerce distribution. However, the market faces challenges from accuracy concerns and user error risks that erode consumer trust.
05/08/2026, 4:47 AM • GlobeNewswire
Danaher Announces Quarterly Dividend
Danaher Corporation announced that its Board of Directors has approved a regular quarterly cash dividend of $0.40 per share, payable on July 31, 2026 to shareholders of record on June 26, 2026.
05/05/2026, 4:30 PM • Benzinga
The plasmid DNA manufacturing market is projected to grow from USD 2.4 billion in 2025 to USD 10.8 billion by 2034, driven by rising demand for gene therapies, DNA vaccines, and CAR-T treatments. North America leads the market with 44.12% share, while Asia-Pacific emerges as a significant growth engine. Major companies are expanding GMP-compliant manufacturing capabilities to meet increasing demand from biopharmaceutical companies and CDMOs.
05/04/2026, 1:00 PM • GlobeNewswire
Why Medtech Giants Are Quietly Paying Up for AI Diagnostics
The global AI in medical imaging market is experiencing rapid growth with a projected $2.20 billion valuation in 2026 and 34.8% CAGR through 2033. Major medtech companies including Danaher, Medtronic, DexCom, and Profound Medical are making strategic acquisitions and expanding AI-powered diagnostic platforms. Hospitals are increasingly prioritizing AI clinical solutions, with 57% ranking them as top technology priorities in 2026-2027, driving demand for validated platforms with real clinical evidence.
04/29/2026, 10:30 AM • Benzinga
The global cell culture media bags market is valued at USD 1.30 billion in 2025 and is projected to reach USD 2.28 billion by 2035, growing at a CAGR of 5.8%. Growth is driven by increased R&D investments in life sciences, adoption of single-use bioprocessing technologies, and automation trends in biopharmaceutical manufacturing. Single-use bags and EVA materials dominate the market segments, with North America leading in market share and Asia Pacific showing the highest growth rate.
04/29/2026, 12:30 AM • GlobeNewswire
The global bulk filtration market is experiencing significant expansion driven by stringent environmental regulations, industrialization, and demand for clean air and water. Key growth drivers include adoption of smart filtration technologies with IoT and AI integration, self-cleaning systems, and advanced membrane filtration methods. The market is expected to grow through 2031 with major players focusing on innovation and sustainability across industries including pharmaceuticals, food and beverage, chemicals, and water treatment.
04/28/2026, 10:00 AM • GlobeNewswire
This Stock Is Up Over 52,700% Since Founding. Should Investors Buy After Its 36% Decline?
Danaher, a leading life sciences company, has underperformed over the past five years due to post-pandemic normalization and weak China sales, but shows signs of recovery with revenue growth resuming in mid-2024. The company's $9.9 billion acquisition of Masimo, a pulse oximetry leader, is expected to add significant revenue and EBITDA. Trading at a 22x P/E ratio—well below its historical 32x average—Danaher presents a potential buying opportunity for long-term investors.
04/24/2026, 2:15 PM • The Motley Fool
The global coagulation analyzer market is projected to grow from USD 4.60 billion in 2025 to USD 7.87 billion by 2035, with a CAGR of 5.55%. Growth is driven by rising blood disorders, increasing surgeries, automation in diagnostics, and cardiovascular disease prevalence. The U.S. market alone is expected to grow from USD 1.50 billion to USD 2.41 billion. Consumables dominate with 64.28% market share, while fully automated systems show the fastest growth at 6.48% CAGR. Hospitals lead end-user segment with 52.84% share, and Asia-Pacific is the fastest-growing region at 7.24% CAGR.
04/22/2026, 10:00 AM • GlobeNewswire
Peers
Statistics
MoreInformation as of 06/24/2026
Company Profile
Danaher Corporation designs, manufactures, and markets professional, medical, research, and industrial products and services in the United States, China, and internationally. The company operates through Biotechnology, Life Sciences, and Diagnostics segments. The Biotechnology segment provides technologies, consumables, services, and solutions that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, and aseptic fill finish; single-use hardware, consumables, and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services for diagnostic and assay development; and healthcare filtration solutions. The Life Sciences segment provides mass spectrometers; bioanalytical measurement systems; flow cytometry, genomics, lab automation, centrifugation, liquid handling automation instruments, antibodies and reagents, and particle counting and characterization; genome sample preparation; microscopes; protein consumables; filtration products; and genomic medicines, such as custom nucleic acid products, and plasmid DNA, RNA, and proteins under the ABCAM, ALDEVRON, BECKMAN COULTER, GENEDATA, IDT, LEICA MICROSYSTEMS, MOLECULAR DEVICES, PALL, PHENOMENEX, and SCIEX brands. The Diagnostics segment offers clinical instruments, consumables, software, and services that hospitals, physicians' offices, reference laboratories and other critical care settings use to diagnose disease and make treatment decisions. The company was formerly known as Diversified Mortgage Investors, Inc. and changed its name to Danaher Corporation in 1984. Danaher Corporation was incorporated in 1969 and is headquartered in Washington, the District Of Columbia.